NCT03539536 2025-11-05Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung CancerAbbViePhase 2 Active not recruiting270 enrolled 1 FDA
NCT02099058 2025-08-14A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsAbbViePhase 1 Active not recruiting237 enrolled